Skip to main navigation
Skip to search
Skip to main content
WashU Medicine Research Profiles Home
Help & FAQ
Home
Profiles
Departments, Divisions and Centers
Research output
Search by expertise, name or affiliation
MS treatment de-escalation: review and commentary
Krzysztof Selmaj
, Hans Peter Hartung
, Marcin P. Mycko
, Igor Selmaj
,
Anne H. Cross
Department of Neurology
Section of Multiple Sclerosis & Neuroimmunology
Institute of Clinical and Translational Sciences (ICTS)
Bursky Center for Human Immunology & Immunotherapy Programs (CHiiPs)
Hope Center for Neurological Disorders
Research output
:
Contribution to journal
›
Review article
›
peer-review
10
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'MS treatment de-escalation: review and commentary'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Neuroscience
Magnetic Resonance Imaging
100%
Immunosuppressive Drug
100%
Natalizumab
100%
Randomized Controlled Trial
100%
Multiple Sclerosis
100%
Intravenous Immunoglobulin
100%
T Lymphocyte Receptor
100%
Ocrelizumab
100%
Polymorphonuclear Cell
100%
Keyphrases
Disease-modifying Therapy
100%
Treatment De-escalation
100%
MS Therapy
100%
MS Patients
28%
Immune System
28%
Extended Interval Dosing
28%
Immunosenescence
28%
High Risk
14%
Infection Risk
14%
Young Patients
14%
Clinical Efficacy
14%
Older Patients
14%
Age Groups
14%
Risk Reduction
14%
Immunosuppressive Agents
14%
Natalizumab
14%
Old Age
14%
Health Risk
14%
Special Circumstances
14%
Multiple Sclerosis
14%
Disease Course
14%
Drug Efficacy
14%
Treatment Discontinuation
14%
Stable Disease
14%
Older People
14%
Multicenter Randomized Controlled Trial
14%
Clinical Activity
14%
Specific Marker
14%
MRI Activity
14%
Continuation Treatment
14%
Number of Subjects
14%
Relapsing-remitting MS
14%
Ocrelizumab
14%
T-cell Receptor Excision Circles
14%
High Efficacy Disease-modifying Therapies
14%
Differential Aging
14%
Immunology and Microbiology
Immunosenescence
100%
Immune System
100%
Granulocyte
50%
Magnetic Resonance Imaging
50%
Immunosuppressive Drug
50%
Intravenous Immunoglobulin
50%
Natalizumab
50%
Multiple Sclerosis
50%
T-Cell Receptor Excision Circles
50%
Ocrelizumab
50%
Drug Efficacy
50%
Infection
50%
Biochemistry, Genetics and Molecular Biology
Immunosenescence
100%
Intravenous Immunoglobulin
50%
Drug Efficacy
50%
Randomized Controlled Trial
50%
Natalizumab
50%
Ocrelizumab
50%
Polymorphonuclear Cell
50%
Magnetic Resonance Imaging
50%
T-Cell Receptor Excision Circles
50%
Pharmacology, Toxicology and Pharmaceutical Science
Diseases
100%
Infection
12%
Randomized Controlled Trial
12%
Immunosuppressive Agent
12%
Immunoglobulin
12%
T Lymphocyte Receptor
12%
Disease Course
12%
Multiple Sclerosis
12%
Natalizumab
12%
Ocrelizumab
12%